Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.7K
Overview
51.7K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

5.7K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.7K
Neurons: The Cell Body and the Dendrites01:23

Neurons: The Cell Body and the Dendrites

7.0K
A typical nerve cell comprises three main components: the cell body, dendrites, and the axon. The cell body, also known as the soma or perikaryon, serves as the central biosynthetic hub housing a nucleus surrounded by cytoplasm containing organelles commonly found in most cells. Notably, Nissl bodies, clusters of the rough endoplasmic reticulum and free ribosomes responsible for protein synthesis, are distinctive features of the neuronal cell body. As neurons age, aggregates of a brown pigment...
7.0K
Humoral Immune Responses01:36

Humoral Immune Responses

83.8K
Overview
83.8K
Cancer Vaccines01:30

Cancer Vaccines

1.0K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.0K
The Extracellular Matrix01:42

The Extracellular Matrix

88.9K
Overview
88.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of plasma irisin levels with amyloid burden in the Alzheimer's disease spectrum.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Nanoscale Epigenetic Profiling of Colorectal Cancer Cell-Derived Exosomes via Single-Vesicle Nanoscopy.

Small methods·2025
Same author

Characterizing nanoscale spatiotemporal defects of multi-layered MoSe<sub>2</sub> in hyper-temporal transient nanoscopy.

Nanophotonics (Berlin, Germany)·2025
Same author

A comprehensive review of dietary supplements mission-specific health and performance enhancement in military soldiers.

Food science and biotechnology·2025
Same author

Rapid Fabrication of Tendon-inspired Ultrastrong, Water-rich Hydrogel Fibers: Synergistic Engineering of Cyano-<i>p</i>-aramid Nanofibers and Poly(vinyl alcohol).

ACS nano·2025
Same author

Imaging Findings of Complications of New Anticancer Drugs.

Korean journal of radiology·2025

Related Experiment Video

Updated: Jan 30, 2026

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus
09:04

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus

Published on: March 28, 2025

765

Dendritic Cell-Targeted pH-Responsive Extracellular Vesicles for Anticancer Vaccination.

Hyuk Lee1, Hongsuk Park2, Hyeong Sup Yu3

  • 1Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro, Bucheon-si, Gyeonggi-do 14662, Korea. ahld1421@naver.com.

Pharmaceutics
|January 30, 2019
PubMed
Summary

This study introduces HDEA@EVAT, a novel pH-responsive extracellular vesicle formulation for cancer immunotherapy. It enhances dendritic cell maturation and CD8+ T-cell activation for improved anticancer vaccine efficacy.

Keywords:
anticancer vaccinedendritic cellsextracellular vesiclespH-responsivetoll-like receptor 4 signaling

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.2K
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
12:54

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

2.4K

Related Experiment Videos

Last Updated: Jan 30, 2026

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus
09:04

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus

Published on: March 28, 2025

765
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.2K
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
12:54

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

2.4K

Area of Science:

  • Biotechnology
  • Immunology
  • Materials Science

Background:

  • Cancer immunotherapy aims for patient-specific treatments, often paralleling infectious disease vaccination strategies.
  • Extracellular vesicles (EVs) are increasingly explored as drug delivery platforms for cancer therapy.

Purpose of the Study:

  • To design and synthesize pH-responsive EVs (HDEA@EVAT) for enhanced cancer immunotherapy.
  • To evaluate the potential of HDEA@EVAT in promoting dendritic cell (DC) maturation and CD8+ T-cell priming.

Main Methods:

  • Engineered EVs (HDEA@EVAT) incorporating hyaluronic acid (HA), DEAP, MPLA, and MUC1 peptide.
  • Investigated DC interaction via toll-like receptor 4 and CD44.
  • Assessed endosomal escape mechanism driven by pH-sensitive DEAP and MUC1 release.
  • Evaluated DC processing and presentation of MUC1 to activate CD8+ T-cells.

Main Results:

  • HDEA@EVAT successfully induced differentiation and maturation of monocytes into dendritic cells.
  • Demonstrated enhanced priming of CD8+ T-cells crucial for cancer therapy.
  • MPLA and HA facilitated DC receptor interaction, while DEAP enabled endosomal escape.
  • MUC1 release and presentation by DCs activated CD8+ T-cells, promoting anticancer immune responses.

Conclusions:

  • HDEA@EVAT exhibits significant anticancer vaccine activity.
  • The formulation effectively bridges DC maturation and CD8+ T-cell activation via MUC1 presentation.
  • Supports the potential of engineered EVs in advancing cancer immunotherapy strategies.